title: Is It Time for Integrase Inhibitors to be the Preferred Regimen for the First-Line Treatment of HIV-1-Infected Naive Patients?
abstract: Thanks to the emergence of combination antiretroviral therapy, HIV/AIDS has been transformed into a manageable, chronic condition in just 30 years and the life expectancy of patients living with HIV is now comparable to those without. Recent data (START) support the strategy of starting all HIV-positive patients regardless of CD4 count. However, patients and physicians want more than just viral control: they want better tolerability, convenience, and few drug-drug interactions. Are the guidelines right in recommending an integrase inhibitor-based regimen as the first-line treatment of choice?
authors.affiliation: Department of Internal Medicine and Infectious Diseases, AIDS Reference Center, Cliniques Universitaires St Luc, Université Catholique de Louvain, Brussels, Belgium.
authors.forename: Jean Cyr
authors.initials: JC
authors.lastname: Yombi
authors.affiliation: Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
authors.forename: Anton L
authors.initials: AL
authors.lastname: Pozniak
mesh_terms: D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans
chemical_list: D019428:HIV Integrase Inhibitors